C4 Therapeutics, Inc. (CCCC)
Pre-Market:
| Previous Close | 6.43 |
| Open | 6.70 |
| Bid | 6.71 x 1000 |
| Ask | 6.75 x 1000 |
| Day's Range | 6.57 - 6.94 |
| 52 Week Range | 1.06 - 11.88 |
| Volume | |
| Avg. Volume | 2,292,861 |
| Market Cap | 463.751M |
| Beta (5Y Monthly) | 3.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.67 |
| Earnings Date | May 06, 2024 - May 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.50 |
GlobeNewswireC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 146,880 shares of the Company’s common stock to one new employee (the “Inducement Grant
- GlobeNewswire
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the Stifel 2024 Targeted Oncology Forum taking place virtually from April 16 – April 17, 2024. Fireside Chat Details:Event: Stifel 2024 Targeted Oncology ForumDate/Time: Tuesday, April 16, 2024 from 10:30 am ET – 10:55 am ET
- GlobeNewswire
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, presented a poster today at the American Association for Cancer Research (AACR) Annual Meeting 2024 highlighting new preclinical data for CFT1946 across multiple models of BRAF V600X mutant colorectal cancer (CRC) and non-small cell lung cancer (NSCLC), additional BRAF inhibitor (BRAFi)-resistant m
